|
|
Targets for anticoagulants
|
|
|
|
Overview: phase III clinical trials of new oral anticoagulants
|
|
|
|
Overview: phase III clinical trials of new oral anticoagulants
|
|
|
|
VKAs are more effective than antiplatelet therapy for stroke prevention
|
|
|
|
RE-LY: A Non-inferiority Trial
|
|
|
|
Stroke or Systemic Embolism
|
|
|
|
Ischaemic/Unspecified Stroke
|
|
|
|
Haemorrhagic Stroke
|
|
|
|
Bleeding and Myocardial Infarction
|
|
|
|
Dabigatran 150 mg vs. 110 mg
|
|
|
|
Common Adverse Events
|
|
|
|
Study Design
|
|
|
|
Primary Efficacy Outcome Stroke and non-CNS Embolism
|
|
|
|
Primary Efficacy Outcome Stroke and non-CNS Embolism
|
|
|
|
Key Secondary Efficacy Outcomes
|
|
|
|
Key Secondary Efficacy Outcomes
|
|
|
|
Time in Therapeutic Range (TTR) INR Data
|
|
|
|
Primary Efficacy Outcome by Quartiles of cTTR Stroke and non-CNS Embolism
|
|
|
|
Primary Safety Outcomes
|
|
|
|
Primary Safety Outcomes
|
|
|
|
Adverse Events and Liver Enzyme Data
|
|
|
|
Summary
|
|
|
|
Baseline patient demographics: comparison of ROCKET AF with previous VKA-controlled trials
|
|
Deel deze pagina met collega's en vrienden: